| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R Gutierrez-Esteinou, J A Greb. Risperidone: an analysis of the first three years in general use. International clinical psychopharmacology. vol 12 Suppl 4. 1997-12-10. PMID:9352340. |
in addition, a prospective comparison with risperidone and clozapine and a subanalysis of the north american trial of risperidone show that risperidone is effective in treatment-resistant schizophrenia. |
1997-12-10 |
2023-08-12 |
Not clear |
| R Gutierrez-Esteinou, J A Greb. Risperidone: an analysis of the first three years in general use. International clinical psychopharmacology. vol 12 Suppl 4. 1997-12-10. PMID:9352340. |
studies also suggest that risperidone reduces the number of days that patients with chronic schizophrenia spend as inpatients. |
1997-12-10 |
2023-08-12 |
Not clear |
| R Gutierrez-Esteinou, J A Greb. Risperidone: an analysis of the first three years in general use. International clinical psychopharmacology. vol 12 Suppl 4. 1997-12-10. PMID:9352340. |
it is concluded that mental health-care workers will need to raise their expectations about the treatment outcome of schizophrenia as a result of the introduction of risperidone. |
1997-12-10 |
2023-08-12 |
Not clear |
| I Bajjoka, T Patel, T O'Sulliva. Risperidone-induced neuroleptic malignant syndrome. Annals of emergency medicine. vol 30. issue 5. 1997-12-05. PMID:9360586. |
risperidone is an antipsychotic drug used for the treatment of schizophrenia. |
1997-12-05 |
2023-08-12 |
Not clear |
| P V Tran, S H Hamilton, A J Kuntz, J H Potvin, S W Andersen, C Beasley, G D Tollefso. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of clinical psychopharmacology. vol 17. issue 5. 1997-11-21. PMID:9315992. |
double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. |
1997-11-21 |
2023-08-12 |
Not clear |
| R S Kern, B D Marshall, T G Kuehnel, J Mintz, J L Hayden, M J Robertson, M F Gree. Effects of risperidone on polydipsia in chronic schizophrenia patients. Journal of clinical psychopharmacology. vol 17. issue 5. 1997-11-21. PMID:9316001. |
effects of risperidone on polydipsia in chronic schizophrenia patients. |
1997-11-21 |
2023-08-12 |
Not clear |
| A Sourande. Risperidone for treatment of childhood schizophrenia. The American journal of psychiatry. vol 154. issue 10. 1997-10-23. PMID:9326842. |
risperidone for treatment of childhood schizophrenia. |
1997-10-23 |
2023-08-12 |
Not clear |
| G Viale, L Mechling, G Maislin, M Durkin, L Engelhart, B J Lawrenc. Impact of risperidone on the use of mental health care resources. Psychiatric services (Washington, D.C.). vol 48. issue 9. 1997-10-22. PMID:9285975. |
the effects of risperidone treatment on health care utilization and treatment costs were examined among patients with treatment-refractory schizophrenia or schizoaffective disorder. |
1997-10-22 |
2023-08-12 |
Not clear |
| G Chouinard, P S Albrigh. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of clinical psychopharmacology. vol 17. issue 4. 1997-09-22. PMID:9241010. |
the current study uses utility analysis to assess economic and quality-of-life benefits of risperidone in patients with chronic schizophrenia. |
1997-09-22 |
2023-08-12 |
Not clear |
| L C Kopala, K P Good, W G Hone. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. Journal of clinical psychopharmacology. vol 17. issue 4. 1997-09-22. PMID:9241011. |
extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. |
1997-09-22 |
2023-08-12 |
Not clear |
| D K Sommers, J R Snyman, M van Wyk, M W Blom, M L Huang, J C Levro. Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients. International clinical psychopharmacology. vol 12. issue 3. 1997-09-22. PMID:9248870. |
the interaction between plasma concentrations of the tricyclic antidepressant amitriptyline and the metabolism of the new antipsychotic risperidone was studied in 12 patients with chronic schizophrenia. |
1997-09-22 |
2023-08-12 |
Not clear |
| P F Buckley, Z Y Ibrahim, B Singer, B Orr, K Donenwirth, P S Bra. Aggression and schizophrenia: efficacy of risperidone. The journal of the American Academy of Psychiatry and the Law. vol 25. issue 2. 1997-08-28. PMID:9213289. |
aggression and schizophrenia: efficacy of risperidone. |
1997-08-28 |
2023-08-12 |
Not clear |
| S Fisman, M Steel. Use of risperidone in pervasive developmental disorders: a case series. Journal of child and adolescent psychopharmacology. vol 6. issue 3. 1997-08-15. PMID:9231311. |
it was postulated that symptoms similar to the positive and negative symptoms of schizophrenia may be observed in the pervasive developmental disorders and might respond favorably to risperidone. |
1997-08-15 |
2023-08-12 |
Not clear |
| G K Kirov, R M Murray, R V Seth, S Feene. Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group. Acta psychiatrica Scandinavica. vol 95. issue 5. 1997-08-14. PMID:9197911. |
observations on switching patients with schizophrenia to risperidone treatment. |
1997-08-14 |
2023-08-12 |
Not clear |
| D V Jeste, M Klausner, M Brecher, C Clyde, R Jone. A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting. Psychopharmacology. vol 131. issue 3. 1997-08-14. PMID:9203234. |
a clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. |
1997-08-14 |
2023-08-12 |
Not clear |
| D V Jeste, M Klausner, M Brecher, C Clyde, R Jone. A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting. Psychopharmacology. vol 131. issue 3. 1997-08-14. PMID:9203234. |
the efficacy and safety of risperidone have previously been demonstrated in controlled clinical trials in hospitalized chronic schizophrenia patients who met strict research criteria. |
1997-08-14 |
2023-08-12 |
Not clear |
| P Hertel, G G Nomikos, B Schilström, L Arborelius, T H Svensso. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 17. issue 1. 1997-08-13. PMID:9194049. |
the enhanced 5-ht output in the fc by risperidone may be of particular relevance for the treatment of schizophrenia when associated with depression and in schizoaffective disorder. |
1997-08-13 |
2023-08-12 |
rat |
| G M Simpson, J P Lindenmaye. Extrapyramidal symptoms in patients treated with risperidone. Journal of clinical psychopharmacology. vol 17. issue 3. 1997-08-12. PMID:9169965. |
the subjects were 523 patients with chronic schizophrenia who, after a 1-week washout period, received placebo, risperidone (2, 6, 10, or 16 mg/day), or haloperidol (20 mg/day) for 8 weeks; the trial was completed by 253 patients. |
1997-08-12 |
2023-08-12 |
human |
| S J Grcevich, R L Findling, W A Rowane, L Friedman, S C Schul. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. Journal of child and adolescent psychopharmacology. vol 6. issue 4. 1997-08-12. PMID:9231318. |
risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. |
1997-08-12 |
2023-08-12 |
Not clear |
| S J Grcevich, R L Findling, W A Rowane, L Friedman, S C Schul. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. Journal of child and adolescent psychopharmacology. vol 6. issue 4. 1997-08-12. PMID:9231318. |
risperidone is a newly available atypical antipsychotic agent that has been reported to be associated with fewer extrapyramidal side effects (eps) than conventional neuroleptics in adults with schizophrenia. |
1997-08-12 |
2023-08-12 |
Not clear |